Results 141 to 150 of about 110,008 (267)

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT‐MI

ESC Heart Failure, EarlyView.
Impact of empagliflozin in patients with and without T2D or CKD in the EMPACT‐MI trial. Baseline characteristics, HF outcomes and subgroup analysis of efficacy endpoints are shown. # Hazard ratios estimated via Cox proportional hazard model (unless indicated otherwise). ^ Rate ratios via negative binomial regression.
Francesco Fioretti, Javed Butler, Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Johann Bauersachs, Antoni Bayes‐Genis, Shaun G. Goodman, Tomasz Gasior, James L. Januzzi, Renato D. Lopes, Piotr Ponikowski, Xavier Rossello, Morten Schou, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Stefan D. Anker   +23 more
wiley   +1 more source

Predicting acute decompensated heart failure using circadian markers from heart rate time series

ESC Heart Failure, EarlyView.
Circadian metrics—amplitude, mesor, and acrophase—derived from a wrist‐worn heart rate monitor can predict acute decompensated heart failure (ADHF) up to 21 days before onset. In 65 post‐ADHF patients, an LSTM model achieved 74% sensitivity, and 73% specificity trained on 21‐day sequences. These findings support circadian rhythm analysis as a promising
Valerie A. A. van Es, Mayke M. C. J. van Leunen, Ignace L. J. de Lathauwer, Cindy C. A. G. Verstappen, René A. Tio, Ruud F. Spee, Lu Yuan, Monica Betta, Giacomo Handjaras, Hareld M. C. Kemps   +9 more
wiley   +1 more source

Acute kidney injury in acute decompensated heart failure: clinical predictors and In-hospital outcomes at a tertiary center. [PDF]

Ann Med
Turkistani Y, Khateb F, Aboul-Enein F, Saddiqi G, Laimooniah D, Qari T, Qari J, Alharbi S.   +7 more
europepmc   +1 more source

Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL‐HF

ESC Heart Failure, EarlyView.
Abstract Aims The EMAIL‐HF trial aims to evaluate whether a digital guideline implementation strategy can increase and accelerate initiation of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors in patients with heart failure (HF). Methods and results EMAIL‐HF is a pragmatic, registry‐based, randomized controlled trial including patients with a ...
Mariam Elmegaard, Lars Køber, Mads Kristian Ersbøll, Theis Lange, Christian Ditlev Tuxen, Mette Rauhe Mouridsen, Trine Kiilerich Lauridsen, Jens Jakob Thune, Peter Godsk Jørgensen, Morten Lamberts, Nadia Paarup Dridi, Peter Bonfils, Morten Petersen, Nis Ottesen Stride, Anders Barasa, Jesper Jensen, Caroline Garred, Emil Fosbøl, Emil Wolsk, John McMurray, Mark Petrie, Morten Schou   +21 more
wiley   +1 more source

Evaluation of the Frequency of Hypokalemia in Patients on Diuretic Therapy for Heart Failure. [PDF]

Cureus
Qaisar HA, Khan H, Rehman AU, Abdullah F.   +3 more
europepmc   +1 more source

A prospective analysis of management and outcomes of worsening heart failure in the outpatient setting

ESC Heart Failure, EarlyView.
Abstract Aims There is growing recognition of the burden and prognostic significance of WHF treated in the outpatient setting. However, there is currently a lack of prospective real‐world data in this area of HF care. This study aims to analyse the natural history of outpatient WHF.
Joseph McCambridge, Fiyinfoluwa Fabamwo, Shadia Taha, Dermot McCaffrey, Matthew Barrett, Ciara Mahon, Kenneth McDonald   +6 more
wiley   +1 more source

Microwave ablation for hepatocellular carcinoma in cirrhotic patients with diuretic-resistant ascites. [PDF]

J Clin Imaging Sci
Blair S, Newcomer J, Raissi D.
europepmc   +1 more source

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials

ESC Heart Failure, EarlyView.
This systematic review identified 24 clinical trials of medical device and surgical interventions for HFpEF, with 16 demonstrating at least safety and feasibility, but little evidence of long‐term benefit. Phenotype‐based responses suggest that certain interventions may benefit specific HFpEF subgroups, yet most trials suffered from heterogeneous ...
Kurdo Araz, Francesco Fioretti, Sara Ladak, Mohammed Obaidan, Javed Butler, Aamir Hameed   +5 more
wiley   +1 more source

The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. [PDF]

, 1988
Gary E. McVeigh, D. B. Galloway, Dennis Johnston   +2 more
openalex   +1 more source

Efficacy and safety of combining a thiazide diuretic with a loop diuretic in decompensated heart failure: A systematic review and meta-analysis. [PDF]

Int J Cardiol Heart Vasc
Bessa R, Martins OC, Mamede I, Franchini AEO, Santos MCF.   +4 more
europepmc   +1 more source